Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osocimab safety and tolerability in ESRD patients on hemodialysis
jRCT2080225371Phase 2Completed
- Sponsor
- Bayer
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of osocimab in end-stage kidney disease (ESKD) (3 arms), sponsored by Bayer. Primary endpoint: Safety and tolerability of osocimab. Started Aug 2020; status: completed.
02
Drugs
osocimab
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCT2080225371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225371.